The currently available biomarkers, including carcinoembryonic antigen, Kirsten rat sarcoma viral oncogene (KRAS), and EGFR mutations, are either not specific to lung cancer, making them unreliable for diagnosis, or require genetic testing, which is not widely available and there may be a long wait for results [21]. This evidence concerns the gene KRAS and lung cancer.